Phase 1/2 For a New PARP1 Inhibitor: EIK1004 (IMP1707) For mCRPC
A new clinical trial has begun testing a promising cancer drug, known as EIK1004 or IMP1707, designed to treat advanced solid tumors, including those that have metastasized to the brain.
This Phase 1/2 trial aims to evaluate the drug’s safety, determine the right dose, and assess its early effectiveness against tumors that are notoriously difficult to treat.
The drug at the center of the trial is a selective PARP1 inhibitor, a type of targeted therapy that blocks an enzyme cancer cells rely on to repair their DNA. By inhibiting this enzyme, the drug aims to kill cancer cells, particularly those with genetic weaknesses, while sparing healthy cells. What sets this drug apart is its ability to cross the blood-brain barrier, a protective shield that often prevents treatments from reaching brain tumors or metastases. This feature makes it a potential option for patients with cancers that have spread to the central nervous system, a group with limited treatment options.
This trial is open to patients with various advanced solid tumors, including prostate cancer.
The development of PARP inhibitors has already changed the landscape for cancers like ovarian, breast, and prostate, particularly for patients with specific genetic mutations (BRCA1/2 are particularly sensitive to PARP inhibitors). This new drug builds on that progress, aiming for greater precision by targeting only PARP1, which may reduce side effects like low blood counts seen with earlier therapies. Its brain-penetrating ability could also fill a critical gap, as brain metastases often signal a poor prognosis and resist standard treatments.